The cell-based seafood startup BlueNalu is setting its sights on US Food and Drug Administration (FDA) approval, which could reshape the entire protein space.
The potential FDA approval, which the company hopes to get by the second half of 2021, would grant BlueNalu enough confidence to prove its commercialization capabilities.
